About Julphar
Julphar, officially Gulf Pharmaceutical Industries, is a pharmaceutical manufacturer based in Ras Al Khaimah. Founded in 1980, it is one of the largest drug makers in the Middle East and is listed on the Abu Dhabi Securities Exchange.
The company produces a wide range of generic medicines, which are versions of established drugs whose patents have expired. Its products cover areas such as pain relief, antibiotics, gastrointestinal medicines, cardiovascular drugs and treatments for chronic diseases.
Insulin is a particularly important product. Julphar built one of the largest insulin manufacturing facilities in the region, supporting access to treatment for people with diabetes. Diabetes is a major public health challenge in the Gulf, with high prevalence rates.
Local pharmaceutical manufacturing reduces reliance on imports and can improve the security of medicine supplies, a concern that became more prominent during the pandemic.
Julphar sells its products in the UAE, across the Middle East and in other markets in Africa and Asia. Generic medicines are important for making healthcare more affordable for patients and health systems.
Pharmaceutical manufacturing is highly regulated. Factories must meet strict quality standards, and products must be approved by health authorities in each market where they are sold.
The company's long history makes it an important part of the UAE's industrial and healthcare sectors, and of the economy of Ras Al Khaimah.
The UAE has emphasised developing a local pharmaceutical and life sciences industry as part of its economic diversification and healthcare strategies.
Julphar is an established manufacturer rather than a startup, and Startups UAE lists it among the UAE's healthcare and pharmaceutical companies.
The company produces a wide range of generic medicines, which are versions of established drugs whose patents have expired. Its products cover areas such as pain relief, antibiotics, gastrointestinal medicines, cardiovascular drugs and treatments for chronic diseases.
Insulin is a particularly important product. Julphar built one of the largest insulin manufacturing facilities in the region, supporting access to treatment for people with diabetes. Diabetes is a major public health challenge in the Gulf, with high prevalence rates.
Local pharmaceutical manufacturing reduces reliance on imports and can improve the security of medicine supplies, a concern that became more prominent during the pandemic.
Julphar sells its products in the UAE, across the Middle East and in other markets in Africa and Asia. Generic medicines are important for making healthcare more affordable for patients and health systems.
Pharmaceutical manufacturing is highly regulated. Factories must meet strict quality standards, and products must be approved by health authorities in each market where they are sold.
The company's long history makes it an important part of the UAE's industrial and healthcare sectors, and of the economy of Ras Al Khaimah.
The UAE has emphasised developing a local pharmaceutical and life sciences industry as part of its economic diversification and healthcare strategies.
Julphar is an established manufacturer rather than a startup, and Startups UAE lists it among the UAE's healthcare and pharmaceutical companies.